Esophageal Carcinoma Clinical Trial
Official title:
Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
Patients with surgically resectable T1N1M0 or T2-4N any M0 esophageal carcinoma will receive six weeks of induction chemotherapy with weekly irinotecan and cisplatin given weeks 1, 2, 4 and 5. Patients will then receive weekly irinotecan, cisplatin, and concurrent radiotherapy with chemotherapy given once weekly, weeks 8,9,11 and 12 during the six weeks of radiotherapy. Patients will be referred for surgery 4-8 weeks after completion of chemoradiotherapy.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02355249 -
Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer
|
Phase 3 | |
| Completed |
NCT01691625 -
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
|
N/A | |
| Not yet recruiting |
NCT05937438 -
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05777707 -
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02527057 -
Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer
|
N/A | |
| Withdrawn |
NCT00636298 -
Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
|
Phase 2 | |
| Recruiting |
NCT06009705 -
Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
|
||
| Recruiting |
NCT04652180 -
Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .
|
N/A | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
| Recruiting |
NCT06199895 -
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00176800 -
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
|
Phase 2 | |
| Completed |
NCT03099382 -
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04607590 -
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
|
||
| Recruiting |
NCT00991094 -
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
|
||
| Completed |
NCT01855854 -
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
|
Phase 2 | |
| Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 | |
| Recruiting |
NCT05795595 -
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1/Phase 2 |